Base de dados : MEDLINE
Pesquisa : D04.210.500.745.432.370.325 [Categoria DeCS]
Referências encontradas : 188 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 19 ir para página                         

  1 / 188 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28476075
[Au] Autor:Jessop S; Whitelaw DA; Grainge MJ; Jayasekera P
[Ad] Endereço:Department of Medicine, University of Cape Town Groote Schuur Hospital, Main Road, 7925 Observatory Cape Town, Cape Town, Western Cape, South Africa.
[Ti] Título:Drugs for discoid lupus erythematosus.
[So] Source:Cochrane Database Syst Rev;5:CD002954, 2017 05 05.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Discoid lupus erythematosus (DLE) is a chronic form of cutaneous lupus, which can cause scarring. Many drugs have been used to treat this disease and some (such as thalidomide, cyclophosphamide and azathioprine) are potentially toxic. This is an update of a Cochrane Review first published in 2000, and previously updated in 2009. We wanted to update the review to assess whether any new information was available to treat DLE, as we were still unsure of the effectiveness of available drugs and how to select the most appropriate treatment for an individual with DLE. OBJECTIVES: To assess the effects of drugs for discoid lupus erythematosus. SEARCH METHODS: We updated our searches of the following databases to 22 September 2016: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and LILACS. We also searched five trials databases, and checked the reference lists of included studies for further references to relevant trials. Index Medicus (1956 to 1966) was handsearched and we approached authors for information about unpublished trials. SELECTION CRITERIA: We included all randomised controlled trials (RCTs) of drugs to treat people with DLE in any population group and of either gender. Comparisons included any drug used for DLE against either another drug or against placebo cream. We excluded laser treatment, surgery, phototherapy, other forms of physical therapy, and photoprotection as we did not consider them drug treatments. DATA COLLECTION AND ANALYSIS: At least two reviewers independently extracted data onto a data extraction sheet, resolving disagreements by discussion. We used standard methods to assess risk of bias, as expected by Cochrane. MAIN RESULTS: Five trials involving 197 participants were included. Three new trials were included in this update. None of the five trials were of high quality.'Risk of bias' assessments identified potential sources of bias in each study. One study used an inappropriate randomisation method, and incomplete outcome data were a concern in another as 15 people did not complete the trial. We found most of the trials to be at low risk in terms of blinding, but three of the five did not describe allocation concealment.The included trials inadequately addressed the primary outcome measures of this review (percentage with complete resolution of skin lesions, percentage with clearing of erythema in at least 50% of lesions, and improvement in patient satisfaction/quality of life measures).One study of fluocinonide cream 0.05% (potent steroid) compared with hydrocortisone cream 1% (low-potency steroid) in 78 people reported complete resolution of skin lesions in 27% (10/37) of participants in the fluocinonide cream group and in 10% (4/41) in the hydrocortisone group, giving a 17% absolute benefit in favour of fluocinonide (risk ratio (RR) 2.77, 95% CI 0.95 to 8.08, 1 study, n = 78, low-quality evidence). The other primary outcome measures were not reported. Adverse events did not require discontinuation of the drug. Skin irritation occurred in three people using hydrocortisone, and one person developed acne. Burning occurred in two people using fluocinonide (moderate-quality evidence).A comparative trial of two oral agents, acitretin (50 mg daily) and hydroxychloroquine (400 mg daily), reported two of the outcomes of interest: complete resolution was seen in 13 of 28 participants (46%) on acitretin and 15 of 30 participants (50%) on hydoxychloroquine (RR 0.93, 95% CI 0.54 to 1.59, 1 study, n = 58, low-quality evidence). Clearing of erythema in at least 50% of lesions was reported in 10 of 24 participants (42%) on acitretin and 17 of 25 (68%) on hydroxychloroquine (RR 0.61, 95% CI 0.36 to 1.06, 1 study, n = 49, low-quality evidence). This comparison did not assess improvement in patient satisfaction/quality of life measures. Participants taking acitretin showed a small increase in serum triglyceride, not sufficient to require withdrawal of the drug. The main adverse effects were dry lips (93% of the acitretin group and 20% of the hydroxychloroquine group) and gastrointestinal disturbance (11% of the acitretin group and 17% of the hydroxychloroquine group). Four participants on acitretin withdrew due to gastrointestinal events or dry lips (moderate-quality evidence).One trial randomised 10 people with DLE to apply a calcineurin inhibitor, pimecrolimus 1% cream, or a potent steroid, betamethasone 17-valerate 0.1% cream, for eight weeks. The study reported none of the primary outcome measures, nor did it present data on adverse events.A trial of calcineurin inhibitors compared tacrolimus cream 0.1% with placebo (vehicle) over 12 weeks in 14 people, but reported none of our primary outcome measures. In the tacrolimus group, five participants complained of slight burning and itching, and for one participant, a herpes simplex infection was reactivated (moderate-quality evidence).Topical R-salbutamol 0.5% cream was compared with placebo (vehicle) over eight weeks in one trial of 37 people with DLE. There was a significant improvement in pain and itch in the salbutamol group at two, four, six, and eight weeks compared to placebo, but the trial did not record a formal measure of quality of life. None of the primary outcome measures were reported. Changes in erythema did not show benefit of salbutamol over placebo, but we could not obtain from the trial report the number of participants with clearing of erythema in at least 50% of lesions. There were 15 events in the placebo group (experienced by 12 participants) and 24 in the salbutamol group (experienced by nine participants). None of the adverse events were considered serious (moderate-quality evidence). AUTHORS' CONCLUSIONS: Fluocinonide cream may be more effective than hydrocortisone in clearing DLE skin lesions. Hydroxychloroquine and acitretin appear to be of equal efficacy in terms of complete resolution, although adverse effects might be more frequent with acitretin, and clearing of erythema in at least 50% of lesions occurred less often in participants applying acitretin. Moderate-quality evidence found adverse events were minor on the whole. There is not enough reliable evidence about other drugs used to treat DLE. Overall, the quality of the trials and levels of uncertainty were such that there is a need for further trials of sufficient duration comparing, in particular, topical steroids with other agents.
[Mh] Termos MeSH primário: Fármacos Dermatológicos/uso terapêutico
Lúpus Eritematoso Discoide/tratamento farmacológico
[Mh] Termos MeSH secundário: Acitretina/efeitos adversos
Acitretina/uso terapêutico
Albuterol/uso terapêutico
Inibidores de Calcineurina/uso terapêutico
Fármacos Dermatológicos/efeitos adversos
Fluocinonida/uso terapêutico
Seres Humanos
Hidrocortisona/uso terapêutico
Hidroxicloroquina/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Tacrolimo/análogos & derivados
Tacrolimo/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Calcineurin Inhibitors); 0 (Dermatologic Agents); 2W4A77YPAN (Fluocinonide); 4QWG6N8QKH (Hydroxychloroquine); 7KYV510875 (pimecrolimus); LCH760E9T7 (Acitretin); QF8SVZ843E (Albuterol); WI4X0X7BPJ (Hydrocortisone); WM0HAQ4WNM (Tacrolimus)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170815
[Lr] Data última revisão:
170815
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170506
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD002954.pub3


  2 / 188 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28084022
[Au] Autor:Alniemi DT; Wetter DA; Bridges AG; El-Azhary RA; Davis MD; Camilleri MJ; McEvoy MT
[Ad] Endereço:Mayo Medical School, Mayo Clinic College of Medicine, Rochester, MN, USA.
[Ti] Título:Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996-2013.
[So] Source:Int J Dermatol;56(4):405-414, 2017 Apr.
[Is] ISSN:1365-4632
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Acute generalized exanthematous pustulosis (AGEP) is a rare skin condition typically caused by medications. The objective of this study was to examine the clinical features, causes, and outcomes of AGEP at a sole tertiary care center. METHODS: A retrospective review of patients with AGEP (European Study of Severe Cutaneous Adverse Reactions score of ≥ 5) seen at Mayo Clinic (Rochester, MN, USA) between January 1, 1996, and December 31, 2013, was conducted. RESULTS: Of 28 patients (mean age at onset: 56 years), 17 (61%) were women. The development of AGEP was attributed to medications in 25 patients (89%), with clindamycin the most common culprit (six patients). Three patients (11%) had mucous membrane involvement, and 21 (75%) showed systemic involvement. Ten patients (36%) received systemic corticosteroids for treatment of AGEP. Skin findings resolved within 15 days in 26 patients (93%) (mean time to resolution: 7.6 days). In three patients (11%), generalized skin eruptions or dermatitis developed weeks to months after the resolution of AGEP. Twenty-four patients (86%) had a personal history of drug reactions before the development of AGEP. CONCLUSIONS: A previous history of drug reactions and clindamycin causation were more common in the present cohort than in prior reports. A small subset of patients experienced new-onset non-AGEP skin eruptions within a few months of the resolution of AGEP.
[Mh] Termos MeSH primário: Pustulose Exantematosa Aguda Generalizada/tratamento farmacológico
Pustulose Exantematosa Aguda Generalizada/etiologia
Antibacterianos/efeitos adversos
Anti-Inflamatórios/uso terapêutico
[Mh] Termos MeSH secundário: Pustulose Exantematosa Aguda Generalizada/patologia
Administração Cutânea
Administração Oral
Adulto
Idoso
Idoso de 80 Anos ou mais
Anti-Inflamatórios/administração & dosagem
Clindamicina/efeitos adversos
Dermatite/etiologia
Quimioterapia Combinada
Feminino
Fluocinolona Acetonida/análogos & derivados
Fluocinolona Acetonida/uso terapêutico
Fluocinonida/uso terapêutico
Seres Humanos
Hidrocortisona/uso terapêutico
Masculino
Meia-Idade
Membrana Mucosa
Prednisona/uso terapêutico
Estudos Retrospectivos
Índice de Gravidade de Doença
Resultado do Tratamento
Triancinolona/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Anti-Inflammatory Agents); 0CD5FD6S2M (Fluocinolone Acetonide); 1ZK20VI6TY (Triamcinolone); 2W4A77YPAN (Fluocinonide); 3U02EL437C (Clindamycin); CT1IX58L9S (fluocinolone); VB0R961HZT (Prednisone); WI4X0X7BPJ (Hydrocortisone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170114
[St] Status:MEDLINE
[do] DOI:10.1111/ijd.13434


  3 / 188 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27664969
[Au] Autor:Alinia H; Moradi Tuchayi S; Smith JA; Richardson IM; Bahrami N; Jaros SC; Sandoval LF; Farhangian ME; Anderson KL; Huang KE; Feldman SR
[Ad] Endereço:Department of Dermatology (Center for Dermatology Research), Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1071, U.S.A.
[Ti] Título:Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring.
[So] Source:Br J Dermatol;176(3):759-764, 2017 Mar.
[Is] ISSN:1365-2133
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Most people with psoriasis have limited disease that could be treated with topicals, but topical efficacy is limited by low short-term adherence. Psoriasis is a chronic disease, and long-term adherence is an even bigger problem. OBJECTIVES: To determine how well medication is used in the long-term topical treatment of psoriasis and to assess the potential of an internet-based reporting intervention to improve treatment adherence and outcomes. METHODS: An investigator-blinded, prospective study evaluated topical fluocinonide adherence in 40 patients with mild-to-moderate psoriasis over 12 months. Subjects were randomized in a 1 : 1 ratio to standard-of-care or internet-based reporting group. Adherence was objectively monitored with Medication Event Monitoring System caps. RESULTS: Fifty per cent of subjects discontinued the treatment. Greater adherence was seen in the intervention group compared with the standard-of-care group (50% vs. 35%, P = 0·08). Psoriasis Area and Severity Index improved more in the intervention group at month 1 (1·61 vs. -0·12, P = 0·003), month 3 (2·50 vs. 0·79, P = 0·025) and month 12 (3·32 vs. 0·34, P = 0·038) than in the standard-of-care group. CONCLUSIONS: This study likely underestimates the challenge of long-term adherence, as adherence tends to be better in research studies than in clinical practice. This study also did not fully account for primary nonadherence. Adherence to topical treatment is low in the short term and decreased further in the long term, a considerable challenge for dermatologists to address. A reporting intervention may be one of the ways we can improve our patients' treatment outcomes.
[Mh] Termos MeSH primário: Fármacos Dermatológicos/administração & dosagem
Fluocinonida/administração & dosagem
Adesão à Medicação
Psoríase/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Cutânea
Adulto
Idoso
Análise de Variância
Registros Eletrônicos de Saúde
Feminino
Seres Humanos
Masculino
Meia-Idade
Satisfação do Paciente
Estudos Prospectivos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Dermatologic Agents); 2W4A77YPAN (Fluocinonide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171105
[Lr] Data última revisão:
171105
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160925
[St] Status:MEDLINE
[do] DOI:10.1111/bjd.15085


  4 / 188 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26646169
[Au] Autor:Hiruta Y; Kanazashi R; Ayano E; Okano T; Kanazawa H
[Ad] Endereço:Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato, Tokyo 105-8512, Japan. kanazawa-hd@pha.keio.ac.jp.
[Ti] Título:Temperature-responsive molecular recognition chromatography using phenylalanine and tryptophan derived polymer modified silica beads.
[So] Source:Analyst;141(3):910-7, 2016 Feb 07.
[Is] ISSN:1364-5528
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Temperature-responsive polymers incorporating molecular-recognition sites were developed as stationary phases for high-performance liquid chromatography (HPLC). The grafted stationary phases consisted of functional copolymers composed of N-isopropylacrylamide (NIPAAm) and N-acryloyl aromatic amino acid methyl esters, i.e., phenylalanine and tryptophan methyl esters (Phe-OMe and Trp-OMe). Three novel temperature-responsive polymers, P(NIPAAm-co-Phe-OMe5), P(NIPAAm-co-Phe-OMe10), and P(NIPAAm-co-Trp-OMe5), were synthesized. These copolymers exhibited a reversible hydrophilic/hydrophobic phase transition at their lower critical solution temperatures (LCSTs). The polymers were grafted onto aminopropyl silica using an activated ester-amine coupling method, and were packed into a stainless steel column, which was connected to an HPLC system. Temperature-responsive chromatography was conducted using water as the sole mobile phase. More hydrophobic analytes were retained longer, and the retention times of aromatic steroids and aromatic amino acids were dramatically increased. This indicated that π-π interactions occurred between the phenyl or indole moieties of phenylalanine or tryptophan, respectively, and the aromatic compounds. Furthermore, the retention times of compounds with hydrogen bond acceptors were higher with P(NIPAAm-co-Trp-OMe5), which contained indole as a hydrogen bond donor, than with P(NIPAAm-co-Phe-OMe5). This indicated that hydrogen bonding occurred between the stationary phase and the analytes. These results indicate that hydrophobic, π-π, and hydrogen bonding interactions all affected the separation mode of the temperature-responsive chromatography, and led to selective separation with molecular recognition. Both temperature-response and molecular recognition characteristics are present in the proposed separation system that utilizes a temperature-responsive polymer bearing aromatic amino acid derivatives.
[Mh] Termos MeSH primário: Resinas Acrílicas/química
Fenilalanina/análogos & derivados
Fenilalanina/química
Dióxido de Silício/química
Triptofano/análogos & derivados
Triptofano/química
[Mh] Termos MeSH secundário: Resinas Acrílicas/síntese química
Aminoácidos/análise
Cromatografia Líquida de Alta Pressão/instrumentação
Estradiol/análise
Estriol/análise
Fluocinonida/análise
Ligações de Hidrogênio
Interações Hidrofóbicas e Hidrofílicas
Naftalenos/análise
Nitrocompostos/análise
Transição de Fase
Testosterona/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (1,5-dinitronaphthalene); 0 (Acrylic Resins); 0 (Amino Acids); 0 (Naphthalenes); 0 (Nitro Compounds); 2166IN72UN (naphthalene); 2W4A77YPAN (Fluocinonide); 3XMK78S47O (Testosterone); 47E5O17Y3R (Phenylalanine); 4TI98Z838E (Estradiol); 7631-86-9 (Silicon Dioxide); 8DUH1N11BX (Tryptophan); FB33469R8E (Estriol)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170131
[Lr] Data última revisão:
170131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151210
[St] Status:MEDLINE
[do] DOI:10.1039/c5an01996f


  5 / 188 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26599999
[Au] Autor:Marable DR; Bowers LM; Stout TL; Stewart CM; Berg KM; Sankar V; DeRossi SS; Thoppay JR; Brennan MT
[Ad] Endereço:Department of Oral Medicine, Carolinas Healthcare System, Charlotte, NC, USA.
[Ti] Título:Oral candidiasis following steroid therapy for oral lichen planus.
[So] Source:Oral Dis;22(2):140-7, 2016 Mar.
[Is] ISSN:1601-0825
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The purpose of this multicentre study was to determine the incidence of oral candidiasis in patients treated with topical steroids for oral lichen planus (OLP) and to determine whether the application of a concurrent antifungal therapy prevented the development of an oral candidiasis in these patients. MATERIALS AND METHODS: Records of 315 patients with OLP seen at four Oral Medicine practices treated for at least 2 weeks with steroids with and without the use of an antifungal regimen were retrospectively reviewed. RESULTS: The overall incidence of oral fungal infection in those treated with steroid therapy for OLP was 13.6%. There was no statistically significant difference in the rate of oral candidiasis development in those treated with an antifungal regimen vs those not treated prophylactically (14.3% vs 12.6%) (P = 0.68). CONCLUSIONS: Despite the use of various regimens, none of the preventive antifungal strategies used in this study resulted in a significant difference in the rate of development of an oral candidiasis in patients with OLP treated with steroids.
[Mh] Termos MeSH primário: Antifúngicos/uso terapêutico
Candidíase Bucal/prevenção & controle
Glucocorticoides/administração & dosagem
Líquen Plano Bucal/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Tópica
Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Betametasona/administração & dosagem
Candidíase Bucal/diagnóstico
Candidíase Bucal/epidemiologia
Clotrimazol/administração & dosagem
Dexametasona/administração & dosagem
Combinação de Medicamentos
Quimioterapia Combinada
Feminino
Fluocinonida/administração & dosagem
Seres Humanos
Incidência
Masculino
Meia-Idade
Estudos Retrospectivos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Drug Combinations); 0 (Glucocorticoids); 0 (Lotrisone); 2W4A77YPAN (Fluocinonide); 7S5I7G3JQL (Dexamethasone); 9842X06Q6M (Betamethasone); G07GZ97H65 (Clotrimazole)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171115
[Lr] Data última revisão:
171115
[Sb] Subgrupo de revista:D
[Da] Data de entrada para processamento:151125
[St] Status:MEDLINE
[do] DOI:10.1111/odi.12399


  6 / 188 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26633679
[Au] Autor:Gibbs LM
[Ad] Endereço:375th Medical Operations Squadron, Family Medicine Clinic, 180 South 3rd Street, Suite 400, Belleville, IL 62220.
[Ti] Título:Beware of the Beetle: A Case Report of Severe Vesicating Dermatitis.
[So] Source:Mil Med;180(12):e1293-5, 2015 Dec.
[Is] ISSN:1930-613X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Outbreaks of Paederus dermatitis have been documented worldwide. A case of Paederus dermatitis from Ethiopia is presented to highlight the importance of this clinical entity in the deployed setting. CASE PRESENTATION: A 31-year-old male presented with a 3- day history of scattered areas of a purulent, vesicating erythematous rash to his mid-back and neck. The largest of these measured 5 × 7 cm with erythematous borders and an erosive center. One to 2 days prior, 15 troops reported similar and less severe vesicating lesions to their extremities and backs. All patients participated in the same outdoor recreational event. A survey of the event's location revealed signs of the Paederus beetle. DISCUSSION: Although a known phenomenon, there are no literature reports of Paederus dermatitis within AFRICOM. Crushing the Paederus beetle against the skin causes an intense rash because of paederin in the hemolymph. Most present with typical linear lesions likely caused by brushing off the beetle from the skin. Fortunately, patients respond favorably to topical steroid treatment. CONCLUSION: Paederus beetle exposure in the deployed setting can impact force health. Increased awareness among providers and personnel should mitigate potential exposure and limit the morbidity associated with this beetle.
[Mh] Termos MeSH primário: Coleópteros
Dermatite de Contato/etiologia
Piranos/efeitos adversos
Pele/fisiopatologia
[Mh] Termos MeSH secundário: Adulto
Animais
Anti-Inflamatórios/uso terapêutico
Vesícula/etiologia
Dermatite de Contato/tratamento farmacológico
Etiópia
Fluocinonida/uso terapêutico
Seres Humanos
Masculino
Militares
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Pyrans); 2W4A77YPAN (Fluocinonide); B8F7J348GJ (pederin)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151204
[St] Status:MEDLINE
[do] DOI:10.7205/MILMED-D-15-00350


  7 / 188 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26424061
[Au] Autor:Lee AS; Perera NJ; Chua EL
[Ad] Endereço:Royal Prince Alfred Hospital, Sydney, NSW angiekow@hotmail.com.
[Ti] Título:Hypoadrenalism secondary to topical corticosteroid-containing skin-lightening cream: danger of over-the-counter cosmetic agents.
[So] Source:Med J Aust;203(7):287, 2015 Oct 05.
[Is] ISSN:1326-5377
[Cp] País de publicação:Australia
[La] Idioma:eng
[Mh] Termos MeSH primário: Insuficiência Adrenal/induzido quimicamente
Insuficiência Adrenal/diagnóstico
Clareadores/efeitos adversos
Cosméticos/efeitos adversos
Fluocinonida/efeitos adversos
Hidrocortisona/análogos & derivados
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Hidrocortisona/efeitos adversos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bleaching Agents); 0 (Cosmetics); 2W4A77YPAN (Fluocinonide); 3X7931PO74 (hydrocortisone acetate); WI4X0X7BPJ (Hydrocortisone)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:151001
[Lr] Data última revisão:
151001
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151002
[St] Status:MEDLINE


  8 / 188 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26367752
[Au] Autor:Draelos ZD
[Ad] Endereço:2444 N Main St, High Point, NC 27262, USA. zdraelos@northstate.net.
[Ti] Título:Stratum corneum absorption kinetics of 2 potent topical corticosteroid formulations: a pilot study.
[So] Source:Cutis;96(2):135-41, 2015 Aug.
[Is] ISSN:2326-6929
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Fluocinonide and halcinonide are class II topical corticosteroids that are indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and generally are applied to affected skin at least twice daily. This pilot study compared the absorption kinetics of cream formulations of fluocinonide and halcinonide in the stratum corneum within a 9-hour period following application. A dermal tape-stripping protocol was used to quantify corticosteroid concentration at 6 sequential depths in the skin of 4 sites on the forearm. Halcinonide and fluocinonide were extracted from the strips and concentrations were measured using liquid chromatography-mass spectrometry. Results demonstrated the immediate absorption of fluocinonide and halcinonide into the stratum corneum within 1 hour of application followed by a sustained release of halcinonide and a steady decline of fluocinonide after peaking.
[Mh] Termos MeSH primário: Fluocinonida/farmacocinética
Glucocorticoides/farmacocinética
Halcinonida/farmacocinética
Pele/metabolismo
[Mh] Termos MeSH secundário: Administração Cutânea
Cromatografia Líquida
Fármacos Dermatológicos/administração & dosagem
Fármacos Dermatológicos/farmacocinética
Fluocinonida/administração & dosagem
Glucocorticoides/administração & dosagem
Halcinonida/administração & dosagem
Seres Humanos
Espectrometria de Massas
Projetos Piloto
Absorção Cutânea
Fita Cirúrgica
Fatores de Tempo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Glucocorticoids); 2W4A77YPAN (Fluocinonide); SI86V6QNEG (Halcinonide)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:150915
[Lr] Data última revisão:
150915
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150915
[St] Status:MEDLINE


  9 / 188 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26291419
[Au] Autor:Fantus SA; Zech LA; Hensley J; Norton SA; Dugan EM
[Ad] Endereço:*Georgetown University School of Medicine, Washington, DC; and †Department of Dermatology, Washington Hospital Center, Georgetown University, Washington, DC.
[Ti] Título:Vegetating Plaques on the Lips. Pyostomatitis vegetans.
[So] Source:Am J Dermatopathol;37(9):699-700, 730-2, 2015 Sep.
[Is] ISSN:1533-0311
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Doenças Labiais/patologia
Pioderma/patologia
Estomatite/patologia
[Mh] Termos MeSH secundário: Anti-Inflamatórios/uso terapêutico
Feminino
Fluocinonida/uso terapêutico
Seres Humanos
Doenças Labiais/tratamento farmacológico
Meia-Idade
Prednisona/uso terapêutico
Pioderma/tratamento farmacológico
Estomatite/tratamento farmacológico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 2W4A77YPAN (Fluocinonide); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:150821
[Lr] Data última revisão:
150821
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150821
[St] Status:MEDLINE
[do] DOI:10.1097/DAD.0000000000000217


  10 / 188 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:25230068
[Au] Autor:Tam CC; Meier MJ
[Ad] Endereço:Christine C. Tam, MD, 3130 Highland Avenue, Cincinnati, Ohio 45267, United States of America; tamce@ucmail.uc.edu.
[Ti] Título:Discrete papular lichen myxedematosus with an unusual segmental presentation.
[So] Source:Acta Dermatovenerol Croat;22(3):224-6, 2014.
[Is] ISSN:1847-6538
[Cp] País de publicação:Croatia
[La] Idioma:eng
[Mh] Termos MeSH primário: Escleromixedema/diagnóstico
[Mh] Termos MeSH secundário: Diagnóstico Diferencial
Quimioterapia Combinada
Fluocinonida/uso terapêutico
Glucocorticoides/uso terapêutico
Seres Humanos
Masculino
Escleromixedema/tratamento farmacológico
Triancinolona/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Glucocorticoids); 1ZK20VI6TY (Triamcinolone); 2W4A77YPAN (Fluocinonide)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:140918
[Lr] Data última revisão:
140918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140918
[St] Status:MEDLINE



página 1 de 19 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde